Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Saturday, 10 / 16 / 2021

scover V7I3  
 PDF Version  pdf32  [ PDF-10.85MB-94pages ]
 

Table of Contents

Editorial

HBV cccDNA: The Stumbling Block for Treatment of HBV Infection
Shousheng Liu, Yongning Xin
Abstract ] [ Html ] [ PDF Full-text ] 195-196 Doi: 10.14218/JCTH.2019.00047

Original Article

Comparing the Efficacy and Safety of Treating Chronic Hepatitis B Infection during Pregnancy with Lamivudine, Telbivudine, and Tenofovir: A Meta-analysis
Shahnaz Sali, Mohammad Darvishi, Mojtaba GhasemiAdl, Meisam Akhlaghdoust, Azin Mirzazadeh, Somayeh Elikaei Behjati, Hossein Sheikh-Zeinolabedini, Shervin Shokouhi, Soheil Tavakolpour
Abstract ] [ Html ] [ PDF Full-text ] 197-212 Doi: 10.14218/JCTH.2019.00021

Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
Xiaoyuan Xu, Bo Feng, Yujuan Guan, Sujun Zheng, Jifang Sheng, Xingxiang Yang, Yuanji Ma, Yan Huang, Yi Kang, Xiaofeng Wen, Jun Li, Youwen Tan, Qing He, Qing Xie, Maorong Wang, Ping An, Guozhong Gong, Huimin Liu, Qin Ning, Rui Hua, Bo Ning, Wen Xie, Jiming Zhang, Wenxiang Huang, Yongfeng Yang, Minghua Lin, Yingren Zhao, Yanhong Yu, Jidong Jia, Dongliang Yang, Liang Chen, Yinong Ye, Yuemin Nan, Zuojiong Gong, Quan Zhang, Peng Hu, Fusheng Wang, Yongguo Li, Dongliang Li, Zhansheng Jia, Jinlin Hou, Chengwei Chen, Jinzi J. Wu, Lai Wei
Abstract ] [ Html ] [ PDF Full-text ] 213-220 Doi: 10.14218/JCTH.2019.00033

Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C
Lai Wei, Jia Shang, Yuanji Ma, Xiaoyuan Xu, Yan Huang, Yujuan Guan, Zhongping Duan, Wenhong Zhang, Zhiliang Gao, Mingxiang Zhang, Jun Li, Jidong Jia, Yongfeng Yang, Xiaofeng Wen, Maorong Wang, Zhansheng Jia, Bo Ning, Yongping Chen, Yue Qi, Jie Du, Jianning Jiang, Lixin Tong, Yao Xie, Jinzi J. Wu
Abstract ] [ Html ] [ PDF Full-text ] 221-225 Doi: 10.14218/JCTH.2019.00018

Hepatitis C Screening: Barriers to Linkage to Care
Sammy Saab, Youssef P. Challita, Lisa M. Najarian, Rong Guo, Satvir S. Saggi, Gina Choi
Abstract ] [ Html ] [ PDF Full-text ] 226-231 Doi: 10.14218/JCTH.2018.00063

TIPS Is Not Associated with a Higher Risk of Developing HCC in Cirrhotic Patients: A Systematic Review and Meta-analysis
Bin Chen, Long Pang, Hao-Bin Chen, Dong-Bo Wu, Yong-Hong Wang, En-Qiang Chen
Abstract ] [ Html ] [ PDF Full-text ] 232-237 Doi: 10.14218/JCTH.2019.00007

Effect of Autologous Bone Marrow Stem Cell Therapy in Patients with Liver Cirrhosis: A Meta-analysis
Chuan-Xin Wu, Deng Wang, Ying Cai, Ao-Ran Luo, Hang Sun
Abstract ] [ Html ] [ PDF Full-text ] 238-248 Doi: 10.14218/JCTH.2019.00008

A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a
Xinyue Chen, Qianguo Mao, Yao Xie, Xiaoguang Dou, Qing Xie, Jifang Sheng, Zhiliang Gao, Xiaoling Zhou, Yingxia Liu, Huanwei Zheng, Shuqin Zhang, Shibo Li, Fusheng Zhu, Yuqin Xu, Mingxiang Zhang, Yaoren Hu, Xiaoping Chen, Yan Huang, Hong Ren, Jidong Jia
Abstract ] [ Html ] [ PDF Full-text ] 249-257 Doi: 10.14218/JCTH.2019.00016

Review Article

HBV cccDNA and Its Potential as a Therapeutic Target
Anjing Zhu, Xinzhong Liao, Shuang Li, Hang Zhao, Limin Chen, Min Xu, Xiaoqiong Duan
Abstract ] [ Html ] [ PDF Full-text ] 258-262 Doi: 10.14218/JCTH.2018.00054

Complementary and Alternative Medicine-related Drug-induced Liver Injury in Asia
Cyriac Abby Philips, Philip Augustine, Sasidharan Rajesh, Praveen Kumar Y, Deepak Madhu
Abstract ] [ Html ] [ PDF Full-text ] 263-274 Doi: 10.14218/JCTH.2019.00024

Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?
Ines Bilic Curcic, Maja Cigrovski Berkovic, Lucija Kuna, Hrvoje Roguljic, Robert Smolic, Silvija Canecki Varzic, Lucija Virovic Jukic, Martina Smolic
Abstract ] [ Html ] [ PDF Full-text ] 275-279 Doi: 10.14218/JCTH.2019.00029

 

Case Report

Amoxicillin-clavulanate-induced Granulomatous Hepatitis: Case Report and Review of the Literature
Avin Aggarwal, Neha Jaswal, Richa Jain, Hussien Elsiesy
Abstract ] [ Html ] [ PDF Full-text ] 280-283 Doi: 10.14218/JCTH.2019.00027m

CASE REPORT

Amoxicillin-clavulanate-induced Granulomatous Hepatitis: Case Report and Review of the Literature

Avin Aggarwal*,1, Neha Jaswal1, Richa Jain2 and Hussien Elsiesy3

1Department of Medicine, University of Arizona, Tucson, AZ, USA
2Department of Pathology, University of Arizona, Tucson, AZ, USA
3Liver consultants of Texas, Baylor All Saints Medical Center, Fort Worth, TX, USA
*Correspondence to: Avin Aggarwal, Department of Medicine, University of Arizona, 1501 N Campbell Ave, Tucson, AZ 85724, USA. Tel: +1-520-626-4555, Fax: +1-520-874-7105, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2019;7(3):280-283 DOI: 10.14218/JCTH.2019.00027
Received: July 8, 2019 Accepted: September 10, 2019 Published onlineSeptember 26, 2019

Abstract

Amoxicillin-clavulanate (AC) is a common cause of drug-induced liver injury, either cholestatic or mixed with hepatitis pattern. Rarely, AC causes granulomatous hepatitis. We report a new case of AC-induced granulomatous hepatitis documented by liver biopsy, with complete resolution of any histological sequelae on a follow-up liver biopsy after AC was withdrawn.

Keywords

Granulomatous hepatitis, Amoxicillin, Clavulanate, Drug-induced liver injury, Liver biopsy

 

 

 

Journal of Clinical and Translational Hepatology 2019 vol. 7, 280-283  [ Html ] [ PDF Full-text ]

© The Authors 2019. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

REVIEW ARTICLE

Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?

Ines Bilic Curcic1,2, Maja Cigrovski Berkovic3, Lucija Kuna4, Hrvoje Roguljic1,5, Robert Smolic6,7, Silvija Canecki Varzic2,8, Lucija Virovic Jukic9 and Martina Smolic*1,4

1Department of Pharmacology, Faculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia
2Department of Diabetes, Endocrinology and Metabolism Disorders, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
3Department for Endocrinology, Diabetes and Metabolism University Hospital Center, “Sestre Milosrdnice”, Zagreb, Croatia
4Department of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health, J. J. Strossmayer University of Osijek, Osijek, Croatia
5Department for Cardiovascular Disease, Osijek University Hospital, Osijek, Croatia
6Department of Gastroenterology and Hepatology, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
7Department of Pathophysiology, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
8Department of Internal Medicine, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
9Department of Gastroenterology and Hepatology, Sisters of Mercy University Hospital, University of Zagreb School of Medicine, Zagreb, Croatia
*Correspondence to: Martina Smolic, Department of Pharmacology, J. J. Strossmayer University of Osijek Faculty of Medicine Osijek, J. Huttlera 4, Osijek 31000, Croatia. Tel: + 385-31-512-800, Fax: +385-31-512-833, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2019;7(3):275-279 DOI: 10.14218/JCTH.2019.00029
Received: July 11, 2019 Accepted: September 9, 2019 Published online: September 15, 2019

Abstract

In recent years, evidence supporting the theory of obesity paradox has increased, showing that obese/overweight people with prevalent chronic diseases experience lower mortality compared with patients of normal weight. So far, evidence is most comprehensive in cardiovascular and chronic renal diseases; however, published studies are prone to many biases, enabling us to reach a definite conclusion. Available data in chronic liver disease is scarce and ambiguous. Obesity is traditionally associated with nonalcoholic fatty liver disease and steatosis in viral hepatitis and as such one would not expect the obesity paradox to be a real possibility in liver disease. Yet, there seem to be new data indicating the opposite – the obesity paradox exists in severe and end-stage liver cirrhosis, which could be attributed to a better lean mass in patients with higher body mass index, meaning that sarcopenia, as one of the most important prognostic factors of survival, is less likely to be present. Nonetheless, the problem of various methodological problems addressing the association between body weight and mortality, which is present both in liver disease and other chronic diseases, are preventing us from attaining an unanimous conclusion. Still, we should be aware that the obesity paradox might be true, especially in severe and end-stage illness. This suggests focusing our efforts toward preserving or building up fat-free mass and decreasing inflammatory activity responsible for catabolism and sarcopenia, and implying that the underlaying cause should be treated.

Keywords

Obesity paradox, Chronic liver disease, NAFLD, NASH, Cirrhosis

 

Journal of Clinical and Translational Hepatology 2019 vol. 7, 275-279  [ Html ] [ PDF Full-text ]

© The Authors 2019. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 logo

You are here: Home Archive Vol 7 Issue 3